The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: -2.25 (-12.50%)
Spread: 0.50 (3.226%)
Open: 15.50
High: 16.50
Low: 15.50
Prev. Close: 18.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Angle hails study find; Eqtec buys plant in France

Wed, 20th Jul 2022 20:50

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

UK Oil & Gas PLC - exploration and production company focused on UK and Turkey - Says it will need to seek further finance before the middle of the fourth quarter to fund oil exploration in Turkey. The UK energy company says the operator of the Resan licence intends to shoot a new, unbudgeted seismic programme before continuing with the Basur appraisal drilling program. This, combined with a longer than expected seismic acquisition period, has required additional working capital and deferred the start of cash flows from a successful Basur well, UKOG explains. "Given the promising positive outlook derived from the company's Basur Phase 1 seismic programme, plus the confirmation from the oil seep that the area has an active light oil petroleum system, the company's focus for the forthcoming 6-9 months will be firmly upon the delivery of Phase 2 seismic and a new Basur appraisal well, now anticipated to be able to add near-term oil production to the company in H1 2023," it says.

----------

Chariot Ltd - Devon, England-based transitional energy firm focused on Africa - Sees material increase in its gas resources offshore Morocco so it can fast track its field development plans for the Anchois gas project. Anchois sees an 81% rise in high confidence 1C contingent resources to 365 billion cubic feet from 201 billion and a 76% rise in 2C contingent resources to 637 billion cubic feet, whilst prospective resources covering three undrilled targets at Anchois have been estimated at some 754 billion cubic feet. The total remaining recoverable resource at Anchois now stands at 1.4 trillion cubic feet.

----------

San Leon Energy PLC - Dublin-based oil & gas exploration company - Signs new USD16.0 million 4-year loan to ELI Malta with 14% coupon. In addition, San Leon subscribes for further 10% of ELI's diluted share capital.

----------

Angle PLC - Surrey, England-based medical diagnostics company - Notes results of a University of Athens study undertaken in early-stage non-small cell lung cancer. Study demonstrates the benefit of analysing epigenetic alterations in circulating tumour cells to assess patient prognosis. The company’s Parsortix technology was used to isolate circulating tumour cells that provide the tell-tale signs of the disease. "We are pleased to report on the use of the Parsortix system for the isolation of CTCs in early-stage NSCLC, showing potential to enable genetic analysis that provides informative prognostic information. This showcases the potential of liquid biopsy, using the Parsortix system, as a promising tool for the assessment of early-stage disease, which is a key priority for healthcare systems world-wide," says Chief Executive Officer Andrew Newland.

----------

Eqtec PLC - Cork, Ireland-based gasification company focused on turning waste into sustainable energy - Says French subsidiary has acquired and intends to upgrade and recommission a 6.5 megawatt electric waste-to-energy gasification plant in Villers-sous-Montrond, France. The plant is expected to generate a revenue of more than EUR10 million a year and construction work is expected to start in the first quarter of 2023. Eqtec said the plant, which has already received an investment of EUR35 million, will be acquired at nominal value, as the recommissioning will require a further investment of EUR30 million.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more
25 Jun 2019 08:16

Angle looks to strengthen balance sheet and extend runway via placement

(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.

Read more
21 Jun 2019 15:26

Angle upbeat on recent cancer research results

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its 'Parsortix' system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non small cell lung cancer (NSCLC) patients.

Read more
21 Jun 2019 12:56

Angle's Parsortix Successfully Investigates Immunotherapy Target

(Alliance News) - Angle PLC on Friday said its Parsortix system has been successfully used as a liquid biopsy to investigate an immunotherapy target in lung cancer.Shares in Angle were up a

Read more
5 Jun 2019 13:04

Angle's Parsortix And HyCEAD Ziplex Systems Identify Cancer In Study

LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex platforms to test for ovarian cancer.The to

Read more
31 May 2019 09:53

Angle reveals positive results from latest Parsortix study

(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Friday.

Read more
26 Apr 2019 12:48

Angle's Parsortix system used in more groundbreaking research

(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer research, demonstrating the role of myeloid-derived suppressor cells (MDSCs) as part of large circulating tumor cell (CTC) clusters, which are 50x more likely to generate metastasis than single CTCs, for the first time.

Read more
26 Apr 2019 12:29

Angle's Parsortix System Used In Further "Groundbreaking" Research

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.The research showed the first the time

Read more
18 Apr 2019 11:35

US Cancer Centre Uses Angle's Parsortix System For Assessments

LONDON (Alliance News) - Angle PLC on Thursday said its ParsortixTM system was used by the University of Texas MD Anderson Cancer Center to develop a new technique for assessing the metastatic of

Read more
12 Apr 2019 15:25

Angle's Parsortix to be used in new Greece study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using its 'Parsortix' system, which could give advance warning of relapse in non small cell lung cancer (NSCLC).

Read more
12 Apr 2019 11:59

University Of Athens Cancer Study To Use Angle's Parsortix System

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said a "leading" customer has set up a multi-centre study using its Parsortix system.The study is being carried out

Read more
7 Mar 2019 13:09

Angle Enrols All 400 Patients In US Breast Cancer Study For Parsortix

LONDON (Alliance News) - Angle PLC on Thursday said it has completed enrolment for a US study of its Parsortix biopsy technology in metastatic breast cancer.All of the 400 subjects required

Read more
7 Mar 2019 09:35

Angle completes enrolment in Parsortix breast cancer study

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that enrolment for its 'Parsortix' FDA clinical study for metastatic breast cancer was now complete.

Read more
28 Feb 2019 13:30

Angle Enrolls First Patients In Ovarian Cancer Study

LONDON (Alliance News) - Angle PLC on Thursday said it has enrolled the first patients in an ovarian cancer verification study, after receiving ethics approval.The study will be divided a a

Read more
25 Feb 2019 10:51

Angle client demonstrates new use for 'Parsortix' system

(Sharecast News) - Liquid biopsy company Angle said on Monday that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet) in Duesseldorf, has published new results in a peer-reviewed journal of work done to harvest circulating tumor cells (CTCs) from diagnostic leukapheresis (DLA) samples.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.